Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

BACKGROUND: Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated. The overarching goal of the Genetic Overlap between Metabolic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamakou, Vasiliki, Hackinger, Sophie, Zengini, Eleni, Tsompanaki, Evgenia, Marouli, Eirini, Serafetinidis, Ioannis, Prins, Bram, Karabela, Athina, Glezou, Eirini, Southam, Lorraine, Rayner, Nigel W., Kuchenbaecker, Karoline, Lamnissou, Klea, Kontaxakis, Vassilis, Dedoussis, George, Gonidakis, Fragiskos, Thanopoulou, Anastasia, Tentolouris, Nikolaos, Zeggini, Eleftheria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090901/
https://www.ncbi.nlm.nih.gov/pubmed/30071838
http://dx.doi.org/10.1186/s12888-018-1826-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090901/
https://www.ncbi.nlm.nih.gov/pubmed/30071838
http://dx.doi.org/10.1186/s12888-018-1826-4

Ejemplares similares